The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action

Francesca Fioredda*, Julia Skokowa, Hannah Tamary, Michail Spanoudakis, Piero Farruggia, Antonio Almeida, Daniela Guardo, Petter Höglund, Peter E. Newburger, Jan Palmblad, Ivo P. Touw, Cornelia Zeidler, Alan J. Warren, David C. Dale, Karl Welte, Carlo Dufour, Helen A. Papadaki

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
46 Downloads (Pure)

Abstract

Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the research and diagnostic advances in the field, real world evidence, arising from international neutropenia patient registries and scientific networks, has shown that the diagnosis and management of neutropenic patients is mostly based on the physicians' experience and local practices. Therefore, experts participating in the European Network for the Innovative Diagnosis and Treatment of Chronic Neutropenias have collaborated under the auspices of the European Hematology Association to produce recommendations for the diagnosis and management of patients across the whole spectrum of chronic neutropenias. In the present article, we describe evidence-and consensus-based guidelines for the definition and classification, diagnosis, and follow-up of patients with chronic neutropenias including special entities such as pregnancy and the neonatal period. We particularly emphasize the importance of combining the clinical findings with classical and novel laboratory testing, and advanced germline and/or somatic mutational analyses, for the characterization, risk stratification, and monitoring of the entire spectrum of neutropenia patients. We believe that the wide clinical use of these practical recommendations will be particularly beneficial for patients, families, and treating physicians.

Original languageEnglish
Pages (from-to)E872
JournalHemaSphere
Volume7
Issue number4
DOIs
Publication statusPublished - Apr 2023

Bibliographical note

Funding Information:
This article is based on the work from Cooperation in Science and Technology (COST) Action CA18233 “European Network for Innovative Diagnosis and treatment of Chronic Neutropenias, EuNet-INNOCHRON” ( https://www.eunet-innochron.eu/ ) supported by COST. PEN and DCD were supported by a NIH R24 AI162637 grant.

Publisher Copyright: © 2023 Wolters Kluwer Health. All rights reserved.

Fingerprint

Dive into the research topics of 'The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action'. Together they form a unique fingerprint.

Cite this